BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/2/2016 9:33:00 AM | Browse: 674 | Download: 1540
Publication Name World Journal of Respirology
Manuscript ID 22368
Country/Territory Portugal
Received
2015-08-27 08:21
Peer-Review Started
2015-08-31 14:42
To Make the First Decision
2015-10-08 16:18
Return for Revision
2015-10-19 01:38
Revised
Second Decision
2016-06-12 10:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-06-29 09:54
Articles in Press
2016-06-29 09:54
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-07-12 11:55
Publish the Manuscript Online
2016-07-19 08:57
ISSN 2218-6255 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Frontier
Article Title New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer
Manuscript Source Invited Manuscript
All Author List Joana Espiga Macedo
Funding Agency and Grant Number
Corresponding Author Joana Espiga Macedo, MD, Consultant of Medical Oncology, Department of Medical Oncology, Centro Hospitalar de Entre Douro e Vouga, Rua Dr. Cândido de Pinho, 4520-211 Santa Maria Da Feira, Portugal. joanamacedo@hotmail.com
Key Words Epidermal growth factor receptor-tyrosine kinase inhibitors; Clonal evolution; Non-small cell lung cancer; Acquired resistance
Core Tip Dramatic changes have occurred in the last decades, concerning the treatment of lung cancer. The knowledge of clinical, pathological and molecular pathways has allowed sub-classifying non-small cell lung cancer (NSCLC), to a point where it has never been reached. The determination of activating mutations of epidermal growth factor receptor (EGFR) has permitted the use of EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib in first, second and maintenance setting. However, acquired resistance develops at some stage of the disease, and second generation TKIs have been developed, but with similar results to traditional chemotherapy. With the arrival of third generation TKIs, a selective target mutational personalized therapy has accomplished better response rates, with a lower toxicity profile in phase Ⅰ clinical trials. The question is should NSCLC patients with exon 19del and L858R point mutation in exon 21 be treated differently, once the driver oncogene is known? On the other hand, if patients with acquired resistance with EGFR T790M, should they also be treated targeting this predominant clone?
Publish Date 2016-07-19 08:57
Citation Macedo JE. New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer. World J Respirol 2016; 6(2): 57-62
URL http://www.wjgnet.com/2218-6255/full/v6/i2/57.htm
DOI http://dx.doi.org/10.5320/wjr.v6.i2.57
Full Article (PDF) WJR-6-57.pdf
Full Article (Word) WJR-6-57.doc
Manuscript File 22368-Review.docx
Answering Reviewers 22368-Answering reviewers.pdf
Audio Core Tip 22368-Audio core tip.mp3
Clinical Trial Registration Statement DeclarationOf_HelsinkiConformation_Statement_20150827070111.docx
Conflict-of-Interest Disclosure Form 22368-Conflict-of-interest statement.pdf
Copyright License Agreement 22368-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s) Informed_Consent_Statement_20150827070046.docx
Institutional Review Board Approval Form or Document Institutional_Review_Board_Statement_20150827065748.docx
Supplementary Material Supplementary_Material_20150827065441.docx
Peer-review Report 22368-Peer-review(s).pdf
Scientific Misconduct Check 22368-Scientific misconduct check.pdf
Scientific Editor Work List 22368-Scientific editor work list.pdf